Apr 7
Unsure About The New ICH Guidelines? TransCelerate Debuts 13 Tools To Help
04/23/2025
If you’ve begun combing through the new ICH GCP E6(R3) guidelines to understand how the updates will affect your clinical research practices and feel just a little lost or overwhelmed, you’ve got help. TransCelerate BioPharma, in a partnership with the Association of Clinical Research Organizations (ACRO), has designed and released 13 tools to support E6(R3) adoption across six focus areas.
Read the full article by Tashan Mistree from Clinical Leader here.
Related Blog Posts
The Impact of ICH E6(R3) – Sponsor and CRO Perspectives
In ACRO and TransCelerate BioPharma’s latest collaboration, Cris McDavid (Senior Director, Global Clinical Operations, Parexel) and Tashan Mistree (Senior Director, Business Operations, Office of Chief Medical Officer, GSK) join this week’s episode to discuss the impact of ICH E6(R3) from their different vantage points in the clinical research industry. Listen to the podcast by Cris McDavid and Tashan Mistree…
Unifying Industry to Better Understand GCP Guidance
In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate…
Better Science, Better Medicine: How Clinical Research Advances Women’s Health
Every International Women’s Day invites reflection: Where have we made strides toward equity, and where do critical gaps remain? In clinical research, we see clear and sometimes sobering examples of how important these reflections can be. Until 1993, women weren’t even required to be included in U.S. clinical trials — an eye-opening fact that illustrates how recently…